This guideline is based on a comprehensive review of the literature on pulmonary nodules
and expert opinion. Although the management pathway for the majority of nodules detected …

Five-year survival rates for non–small cell lung cancer (NSCLC) range from 14% to 49% for
stage I to stage IIIA disease, and are< 5% for stage IIIB/IV disease. Improvements have been …

Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC)
is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative …

Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …

Purpose This study compared treatment outcomes of stereotactic body radiation therapy
(SBRT) with those of surgery in stage I non-small cell lung cancer (NSCLC). Methods and …

Importance The incidence of early-stage non–small cell lung cancer (NSCLC) among the
elderly is expected to rise dramatically owing to demographic trends and increased …

Background Video-assisted thoracoscopic surgery (VATS) lobectomy and stereotactic
ablative radiotherapy (SABR) are both used for early-stage non-small-cell lung cancer. We …

Lung cancer is the leading cause of cancer mortality, and radiotherapy plays a key role in
both curative and palliative treatments for this disease. Recent advances include stereotactic …

PURPOSE: The incidence of early-stage non-small cell lung cancer (NSCLC) among older
adults is expected to increase because of demographic trends and computed tomography …

BACKGROUND The authors evaluated the efficacy, patterns of failure, and toxicity of
stereotactic ablative radiotherapy (SABR) for patients with medically inoperable, clinical …